Sunesis Pharmaceuticals

US: SNSS

$46.2m market cap

$0.42 last close

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

Investment summary

On 18 March, Sunesis released the first assessments of the 400mg cohort in its ongoing dosing study of vecabrutinib for B-cell malignancies. Two (of three) patients in this cohort showed stable disease (SD), with one showing a 48% response. These results are largely similar to those seen with the 300mg cohort (one near-responder SD, two stabilized SD, and one progressor). We would like to have seen more definitive activity in this cohort, but there is still the possibility that Sunesis will cross the line of generating partial responses (PRs) in the upcoming 500mg cohort.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.2 (25.7) (26.6) (74.80) N/A N/A
2019A 2.1 (23.3) (23.3) (26.78) N/A N/A
2020E 0.0 (28.0) (28.5) (24.32) N/A N/A
2021E 0.0 (32.7) (35.7) (29.22) N/A N/A
Industry outlook

Sunesis is an oncology company with an early-stage asset with a validated target for the treatment of B-cell malignancies.

Last updated on 31/03/2020
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 5.8
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (57.9) 22.9 (65.9)
Relative* (51.9) 53.6 (62.6)
52-week high/low US$1.7/US$0.3
*% relative to local index
Key management
William Quinn Chief Financial Officer and Senior Vice Presi

Content on Sunesis Pharmaceuticals